The AI drug development boom has not yet subsided, while the more sci-fi-inspired "space-based drug production" is already set to become the next trending buzzword.

Space pharmaceutical manufacturing, also known as microgravity pharmaceutical production, is an advanced interdisciplinary field at the intersection of biotechnology and aerospace science. Scientists utilize specialized space environments such as microgravity and cosmic radiation provided by space stations and sounding rockets to conduct research on key stages of drug development and production.

This field is not confined to theoretical speculation—Europe's Zeprion-2 mission has delivered microfluidic chips to the space station, focusing on complex protein crystallization; South Korea's Space LYNTech conducted the world's first fully automated protein crystallization experiment, requiring no astronaut intervention; since 2023, SpaceMD, a subsidiary of Redwire specializing in space pharmaceuticals, has deployed 54 PIL-BOX systems to the International Space Station, successfully crystallizing 45 compounds, including insulin and key molecules for various cancers and cardiovascular diseases.

Recently, SpaceMD welcomed two heavyweight advisors—Paul Reichert, former head researcher at Merck who led early-stage crystallization studies for Keytruda, and Niki Werkheiser, former NASA director of technology maturation who oversaw over $1.5 billion in technology investments. The top minds from the pharmaceutical and aerospace industries are converging, with a clear focus on new drug development in microgravity environments.

Humanity has begun to cast its gaze toward the microgravity environment 400 kilometers above, seeking to create life-saving pills between the stars.

1、Why go into space?

Pharmaceutical engineers on Earth share a common concern: gravity.

When protein molecules crystallize in solution, gravity-induced convection and sedimentation interfere with their orderly arrangement, leading to defects in the crystal structure. This directly affects the solubility, purity, and stability of the drug, thereby limiting its efficacy.

The microgravity environment in space provides a nearly perfect solution. Here, buoyancy convection and sedimentation are almost eliminated, allowing molecules to arrange themselves freely according to their thermodynamic properties, forming larger, more uniform, and purer protein crystals.

Purer crystals mean higher bioavailability, more uniform structures imply longer shelf life, and superior solubility may enable drugs originally limited to intravenous injection to be administered via subcutaneous routes. It is this enticing prospect that has transformed space-based pharmaceutical production from a laboratory concept into a new frontier where nations are vying for strategic positioning.

Currently, this field is transitioning from research to early-stage commercialization, primarily driven by collaborations between government space agencies and major pharmaceutical companies, with a focus on two key directions: high-quality protein crystallization and disease model construction.

、
The first-mover advantage of U.S. companies largely stems from the maturity of the commercial space ecosystem. SpaceX's Falcon 9 rocket has significantly reduced the cost of space access, providing high-frequency, low-cost launch options for companies like Varda and Redwire.

SpaceMD is a typical representative in this field. Its PIL-BOX technology is specifically designed for growing seed crystals in microgravity, after which the crystals are sold or licensed to pharmaceutical companies for re-formulating existing drugs or developing new therapies. Varda Space Industries, on the other hand, follows a different approach—launching unmanned spacecraft to complete drug crystallization in orbit and then returning the products to Earth. To date, Varda has successfully brought three spacecraft back, with one still operating in orbit.
Unlike the US approach driven by corporate initiatives, the UK opted for regulatory leadership first.

In March 2026, the UK Space Agency, in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA), the Office for the Regulation of Science and Technology under the Department for Science, Innovation and Technology, and the Civil Aviation Authority, jointly released a comprehensive set of supportive measures for on-orbit pharmaceutical manufacturing, covering four components: regulatory guidelines, case studies, regulatory sandboxes, and supply chain engagement.

Among them, the regulatory sandbox mechanism is particularly noteworthy. This concept originates from the field of financial technology, and the core logic is to allow companies to test innovative solutions in a controlled environment, with regulatory agencies involved in observing and jointly identifying and resolving regulatory applicability issues.

Introducing the sandbox mechanism into space pharmaceuticals means that companies do not have to blindly take risks in a "regulatory vacuum" or "regulatory mismatch". MHRA will intervene and provide guidance in the early stages to help companies clarify which safety, quality, and efficacy standards need to be met for drugs manufactured in space.

The UK side claims that the demonstration tasks that have been carried out have accumulated experience for regulatory practice. For example, the ForgeStar 1 mission from Space Forge and the ELSA-D mission from Astroscale UK have demonstrated that in orbit manufacturing technology is feasible from a licensing perspective. BioOrbit has received a £ 250000 feasibility study funding to explore a scalable system for biopharmaceutical crystallization in space.

Previously, MHRA had released what is considered the world's first regulatory framework for "decentralized manufacturing". The UK clearly hopes to replicate this experience in the field of space pharmaceuticals by taking the lead in establishing regulatory standards and attracting global companies to land.

2、Chinese coordinates

According to QYResearch research, the global microgravity biopharmaceutical market is expected to reach approximately $65 million by 2025 and $129 million by 2032, with a compound annual growth rate (CAGR) of 10.2% from 2026 to 2032. The CAGR for the Chinese market is expected to be higher, reaching 20.0%.

At the national strategic level, space pharmaceuticals have been officially included in the top-level design of China's aerospace development. The white paper "China's Aerospace" clearly defines space pharmaceuticals as a new form of space industry. In November 2025, the National Space Administration issued the "Action Plan for Promoting High Quality and Safe Development of Commercial Aerospace (2025-2027)", which further listed "space biopharmaceuticals" as one of the key areas to support commercial aerospace entities in strengthening original innovation. In May 2026, the Space Biomedical Innovation Consortium was officially established, marking the beginning of the formation of industrial synergy mechanisms.

The clear policy provides direction for the allocation of scientific research resources, and the Chinese space station has become the core experimental platform carrying these strategic goals. This permanent manned scientific platform is equipped with specialized scientific experiment cabinets and has the ability to conduct experiments in microgravity materials science and biotechnology. In recent years, Chinese scientists have systematically advanced multiple studies such as protein crystallization and cell culture on the space station.

In July 2025, the Tianzhou-9 cargo spacecraft will deliver 23 scientific experimental materials to the space station, among which the "Research on the Biological Functions of Nucleic Acid Lipid Nanocarriers in Microgravity Environment" project has achieved a breakthrough. In orbit experiments have shown that under microgravity conditions, the uptake efficiency of nucleic acid drugs by cells is significantly improved, the expression level of disease-related proteins rapidly decreases, and the therapeutic effect is significantly better than that of ground parallel controls. This discovery suggests that microgravity environments may provide new experimental models and treatment approaches for diseases that are difficult to cure on the ground.

In the field of protein crystallization, the Space Biology Center of Zhejiang University has completed its fifth space experiment. Its microgravity protein crystallization device is equipped with 7 protein samples, including DNA polymerase and transferase. The research team stated that "even if the accuracy of protein structure is improved by 10%, it is still very meaningful in medicine".

The industrialization process is also accelerating. In March 2026, China Science and Space Technology and the Chinese Academy of Sciences Shanghai Institute of Materia Medica signed a cooperation agreement to carry out joint technological research around space pharmaceuticals; The independently developed Lihong series aircraft has completed its maiden flight, and the parachute landing and recovery technology of the payload compartment has been successfully verified. In May of the same year, the Zhongke Aerospace Innovation Research Institute was unveiled in Huangpu, Guangzhou, focusing on the construction of a suborbital microgravity experimental platform and an orbital level space manufacturing platform, targeting future industrial needs such as space biomedicine.

At the same time, the Guangdong Hong Kong Macao Greater Bay Area is actively expanding its layout. In April 2026, Guangdong Aerospace Science and Technology Research Institute visited Zhongke Zhongshan Drug Innovation Research Institute for exchange. The two sides plan to cooperate in three directions: macromolecular drug crystal growth, astronaut health protection drug screening, and the impact of microgravity on the microstructure of sugar substances.
 

However, there is still a significant gap between being able to experiment and being able to make drugs.

By international comparison, the PIL-BOX system of SpaceMD in the United States has achieved 54 sets of equipment in orbit operation, forming a standardized and repeatable commercial experimental capability. Behind it is Redwire's rapidly iterating closed-loop mechanism - design, manufacturing, launch, recovery, and optimization can be completed within a few months.

However, China's current space station experiments are still dominated by state led scientific research projects, and the admission process, approval efficiency, and cost sharing mechanism for commercial payloads still need to be further integrated.
 

3、 "Space Value Added"

The challenges faced by space pharmaceuticals are equally real.

Cost is the first hurdle. Even with the continuous advancement of reusable rocket technology, the cost of a single launch is still in the millions of dollars, and the electricity, data return, and sample return for in orbit experiments are all expensive. The success of the business model depends on whether the performance improvement of drugs manufactured in space can justify the high "space added value".

Science itself still needs to be deepened. The promoting effect of microgravity on protein crystallization is clear, but how strong is the causal chain between improving crystal quality and ultimately enhancing drug performance? Which molecules are most sensitive to this process? What steps can be completed in space, and which ones are more suitable for ground seeding? These fundamental questions all need to be answered.

Global coordination of regulation is also a challenge. If a drug passes the review based on space manufacturing in the United States, does it need to re evaluate the rationality of the "space part" when it is launched in China? Can a multilateral mutual recognition mechanism be established? These issues not only concern the industry, but also involve drug accessibility and global health equity.
The future development height of this field depends on whether it can systematically prove that the space environment can produce breakthrough results with clear commercial value. Once the "space added value" is confirmed, there will be a common pivot for crossing the three hurdles of cost, science, and regulation.

At the same time, a more structural turning point is approaching. The International Space Station is planned to be decommissioned under controlled conditions by 2030. If commercial alternatives are not in place as scheduled, the Chinese space station may become the only stable large-scale manned research platform in near Earth orbit. This means that global space pharmaceutical research may face a temporary 'platform drought', and countries with independent space stations will have access to scarce in orbit experimental resources.

Before that, every crystal grown under microgravity was laying answers. The new drugs of the next decade may come from among the stars.